In this episode, I unpack the recent U.S. military operation that led to Nicolás Maduro’s capture and ongoing narco-terrorism proceedings in New York, and look at what this actually means for health and pharma supply chains in and around Venezuela.

Rather than debating the politics, I focus on access to medicines, sanctions and logistics friction, and two working scenarios: a managed transition with selective relief versus a prolonged standoff where Venezuela remains a high-friction, low-priority market.

I also explore how spillover effects, migration, shifting demand, and NGO procurement, could impact neighboring health systems.

Finally, I translate this into practical actions for pharma and med-tech leaders: mapping exposure, separating humanitarian and commercial channels, tightening sanctions and compliance processes, build ...